OnKure Therapeutics OKUR 深 沪
等待开盘 10-27 09:30:00 美东时间
2.465
-0.055
-2.18%
华盛通- 最 高2.625
- 今 开2.53
- 成交量 10.83万股
- 最 低 2.38
- 昨 收 2.52
- 总市值 9982.34万
- 52周最高 5.38
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 2.01
- 委 比 -68.67%
- 总股本 4049.63万
- 历史最高 19.9992
- 量 比 0.81
- 振 幅 9.72%
- 历史最低 1.70
- 每 手 1
- 风险率 0.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
OnKure Therapeutics announced that its senior management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14-16, 2026. The company, focused on developing precision medicines for underserved vascular anomalies and cancers, will host one-on-one meetings with interested investors. For more information, visit www.onkure.com.
08-31 12:00
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14
Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.
08-15 01:15
OnKure Therapeutics Q2 EPS $0.31 Beats $(0.54) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $(0.54) by 158.49 percent. This is a 127.19 percent increase over losses of $(1.14) per share from the same period last year.
08-05 04:28
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $21
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $27 to $21.
07-20 23:52
OnKure Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.
OnKure Therapeutics shares are trading lower after the company reported worse-t...
05-06 23:23
OnKure Therapeutics Q1 EPS $(1.11) Misses $(0.64) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.64) by 73.44 percent. This is a 6.72 percent increase over losses of $(1.19) per share
05-06 04:39
OnKure Therapeutics Enters Into Securities Purchase Agreement For Private Placement Raising Gross Proceeds Of ~$150M
-- Financing led by Access Biotechnology with participation from new and existing investors-- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies –
03-27 20:12
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
